Impact of insulin pump therapy on glycemic control , and body mass index on Type 1 diabetes mellitus, Tripoli Libya.
DOI:
https://doi.org/10.54361/ljmr15.1.03Keywords:
Insulin pump therapy, Type 1 diabetes mellitus, HbA1C, Body mass index( BMI).Abstract
Background: Diabetes mellitus is a chronic disease characterized by hyperglycemia that leads after many years to chronic micro vascular and macro vascular complications .Type 1 diabetes is a life- threatening chronic condition requiring continuous and life-long management that can be stressful for patients and their caregivers. Objectives is to evaluate the effectiveness of insulin pump therapy on glycemic control , and body mass index in Type 1 DM. Patients and Method: this is retrospectively studied the profiles of 73patients were on insulin pump therapy (28 males and 45 females) attending insulin pump clinic at the National Diabetes& Endocrinology center in Tripoli, Libya, from the period of first January 2014 to last December 2017. Data collected included demographic, clinical,HBA1C level ,and body mass index before, at six months, and after one year of nsulin pump therapy use.Results:61.5% were females ;mean age of patients was 29.08± 8.68 years . The mean duration of diabetes was 11.14±6.54 years. 50.7% of them were students, 83.6% were University students. The most of patients , 91.8% have no complications of diabetes. The mean HbA1C values improved from 8.29 ± 1.55 at initiation of the insulin pump therapy, to 7.27 ± 1.08 at the end of 6 months ,and to 7.35 ± 1.30 at the end of one year, with p value of 0.000. Conclusion: also The Mean body weight has no change from the start of therapy to the end of one year study (from 25.07 ± 4.54 at start to 25.18 ± 4.74 at end of 6 months to 26 ± 5.14 at end of study with p value 0.000. the impact of insulin pump therapy was positive in maintaining a good glycemic control in most of participants, and unchanged in the body mass index.
References
leonard MJ,Reeves GD(2001) Continuous subcutaneous insulin infusion:a comprehensive review of insulin pump therapy .Arch intern Med19:2293-2300,. DOI: https://doi.org/10.1001/archinte.161.19.2293
Davies AG,Baun JD(1988). A decade of insulin infusion pumps .Arch Dis Child 63:329-332 DOI: https://doi.org/10.1136/adc.63.3.329
Mecklenburg R ,benson J, Becker N ,Brazel P ,Fredlund P , Metz R , Nielson R , Saner C ,Steenrod W (1982).clinical use of the insulin infusion pump in 100 patients with type 1 diabetes . N Engl J Med 307 : 513-518 . DOI: https://doi.org/10.1056/NEJM198208263070901
Diabetes Control and Complications Trial Research Group.(1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus.NEngl J Med 329:977–86. DOI: https://doi.org/10.1056/NEJM199309303291401
UK Prospective Diabetes Study (UKPDS) Group.(1998). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837–53. DOI: https://doi.org/10.1016/S0140-6736(98)07019-6
Pickup J, Keen H.(2002). Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25:593–8. DOI: https://doi.org/10.2337/diacare.25.3.593
Nielsen S, Kain D, Szudzik E, Dhindsa S, Garg R, DandonaP. (2005).Use of continuous 31:843–8 DOI: https://doi.org/10.1177/0145721705283078
Faten B.R, Nadia A, Wesal H, Nour A, Nadia B. G.(2016). First Libyan Experience with Insulin Pump Therapy: Impact on Glycemic Control and Patients Satisfaction.Ibnosina Journal of Medicine and Biomedical Sciences · November 8(6) :264 -270. DOI: https://doi.org/10.4103/1947-489X.210242
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN,(2010).for the Star 3 Study Group; Effectiveness of sensor augmented insulin pump therapy in type1 diabetes; New Engl J Med 363(4):311-20. DOI: https://doi.org/10.1056/NEJMoa1002853
Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, et al.(2005).Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients.Diabet Med 22:1037–46. DOI: https://doi.org/10.1111/j.1464-5491.2005.01597.x
Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M,Tamborlane WV.(2002). Insulin pump therapy in pediatrics: a therapeuticalternative to safely lower HbA1C levels across all agegroups. Pediatric Diabetes 3:10–5. DOI: https://doi.org/10.1034/j.1399-5448.2002.30103.x
Plotnick LP, Clark LM, Brancati FL, Erlinger T.(2003). Safety andeffectiveness of insulin pump therapy in children and adolescentswith type 1 diabetes. Diabetes Care 26:1142–6. DOI: https://doi.org/10.2337/diacare.26.4.1142
American Association of Diabetes Educators.(2003). Education forcontinuous subcutaneous infusion pump users. Diabetes Educ29:97–9. American Diabetes Association.(2004).Continuous subcutaneousinsulin infusion. Diabetes Care 27(Suppl 1):S110.11.. Insulin pump therapy: situations and solutions. DOI: https://doi.org/10.1177/014572170302900113
Lippincotts Prim Care Pract1997;1:519–26.12. deWeerdt I, Visser AP, Kok G, van der Veen EA. Determinantsof active self-care behavior of insulin treated patients with diabetes:implications for diabetes education. SocSci Med 1999;30:605–15. DOI: https://doi.org/10.1016/0277-9536(90)90159-P
Bott U, Jorgens V, Grusser M, Bender R, Mühlhauser I, BergerM.(1994). Predictors of glycemic control in type 1 diabetic patientsafter participation in an intensifiedtreatment and teaching program.Diabet Med 11:362–71 DOI: https://doi.org/10.1111/j.1464-5491.1994.tb00287.x
Reda E, Von Reitzenstein A, Dunn P.(2007). Metabolic control withinsulin pump therapy: the Waikato experience. N Z Med J 120:2401–12.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Bahlul Ben Masaud, Darin meeteig, Khawla ameed, Najwi mudallal, Salsabil Keshlaf, Enas azzabi, Ibtihal shagrouni, Walid shekiry, Sanira Nowara, Ayman Derbash, Hamida Benhamed (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
